REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease ...Middle East

PR Newswire - News
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of CLN2 disease, the most common form of Batten disease Patient dosed under a single-patient investigator-initiated study of RGX-181 Company announces approval of CTA for...

Hence then, the article about regenxbio reports update on advancement of programs for cln2 disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease )

Apple Storegoogle play

Last updated :

Also on site :